ClinicalTrials.gg

Program

Doxorubicin

Also written as “doxorubicin hydrochloride”, “Doxorubicin hydrochloride (liposomal)” and “doxorubicin”.

Its studies are mostly in Breast Neoplasms · Sarcoma · Lymphoma, Large B-Cell, Diffuse · Carcinoma, Hepatocellular · Sarcoma, Kaposi, led by 16 companies.

Furthest: phase 3, since Jan 25, 200534 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly50 open or runningphase 2since Jan 25, 2005Jan 25, 2005none ahead
Johnson & Johnson40 open or runningphase 3since Feb 9, 2005Jan 31, 2005none ahead
Sanofi40 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Sequus Pharmaceuticals40 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Amgen30 open or runningphase 3since Mar 31, 2003Jul 5, 2000none ahead
InSightec22 open or runningphase 2since Nov 7, 2022Nov 7, 2022none ahead
Philogen20 open or runningphase 2since May 25, 2010May 25, 2010none ahead
Teva Pharmaceutical Industries20 open or runningphase 2since Oct 24, 2005Oct 24, 2005none ahead
alfacell10 open or runningphase 3since Nov 1, 1999Nov 1, 1999none ahead
bio-cancer-treatment-international-limited10 open or runningphase 1since Sep 30, 2009Sep 30, 2009none ahead
presage-biosciences10 open or runningphase 1since Jan 22, 2017Jan 22, 2017none ahead
sopherion-therapeutics10 open or runningphase 3since Feb 17, 2006Feb 17, 2006none ahead
spirovant-sciences-inc11 open or runningphase 2since Jul 18, 2024Jul 18, 2024Dec 31, 2026phase 2 · NCT06526923
sutphin-drugs10 open or runningearly phase 1since Jun 3, 2019Jun 3, 2019none ahead
Valerio Therapeutics10 open or runningphase 3since Jul 26, 2012Jul 26, 2012none ahead
zivena10 open or runningphase 2since May 11, 2004May 11, 2004none ahead

Also a collaborator on its studies: AbbVie and PharmaMar.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 19 studies since Nov 1, 1999.

  1. Aug 16, 2006Phase 2 study in Breast NeoplasmsSanofi · NCT00365365 · 214 enrolled · United States
  2. Apr 17, 2007Phase 2 study in Carcinoma, DuctalSanofi · NCT00461344 · 20 enrolled
  3. Sep 30, 2009bio-cancer-treatment-international-limited's first study: phase 1 study in NeoplasmsNew to bio-cancer-treatment-international-limitedbio-cancer-treatment-international-limited · NCT00988195 · 15 enrolled · Hong Kong
  4. May 25, 2010Philogen's first study: phase 2 study in Breast NeoplasmsNew to PhilogenPhilogen · NCT01131364 · 29 enrolled · Italy
  5. Jul 26, 2012Valerio Therapeutics's first study: phase 3 study in Carcinoma, HepatocellularNew to Valerio TherapeuticsValerio Therapeutics · NCT01655693 · 397 enrolled · United States, Austria, Belgium and more
  6. Mar 14, 2013Phase 1 study in NeoplasmsJohnson & Johnson · NCT01815294 · 54 enrolled · United States, Belgium, Spain and more
  7. Feb 24, 2014Phase 1 study in SarcomaPhilogen · NCT02076620 · 29 enrolled · Germany, Italy
  8. Jan 29, 2016Phase 1 study in Neoplasm MetastasisEli Lilly · NCT02677116 · 68 enrolled · United States, Japan
  9. May 24, 2016Phase 1 study in SarcomaEli Lilly · NCT02783599 · 51 enrolled · United States, France, Italy and more
  10. Jan 22, 2017presage-biosciences's first study: phase 1 study in SarcomaNew to presage-biosciencespresage-biosciences · NCT03056599 · 23 enrolled · United States
  11. Sep 13, 2017Phase 1 study in SarcomaEli Lilly · NCT03283696 · 24 enrolled · United States, Germany, Italy
  12. Jun 3, 2019sutphin-drugs's first study: early phase 1 study in Lymphoma LeukemiaNew to sutphin-drugssutphin-drugs · NCT03975205 · 500 enrolled · India
  13. Nov 7, 2022InSightec's first studies: 2 phase 2 studies in Brain NeoplasmsNew to InSightecInSightec · NCT05615623, NCT05630209
  14. Jul 18, 2024spirovant-sciences-inc's first study: phase 2 study in Cystic FibrosisNew to spirovant-sciences-incspirovant-sciences-inc · NCT06526923 · 15 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Cystic Fibrosisspirovant-sciences-inc · NCT06526923

TargetBeta

TOP2A →read by rule
“DNA topoisomerase II alpha inhibitor; DNA inhibitor”ChEMBL 37, by rule

Other programs on TOP2A

ProgramCompanyFurthest phaseStudies
EtoposideruleHoffmann-La Rochephase 328
amrubicinruleBristol-Myers Squibbphase 39
Daunorubicinrulekura-oncology-incphase 37

Studies

All 34 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06526923Cystic Fibrosis · United States2Recruitingspirovant-sciences-incDec 31, 202615
NCT05630209Brain Neoplasms · United States2Active, not recruitingInSightecJun 202610
NCT05615623Brain Neoplasms · Canada2Active, not recruitingInSightecJun 202610
NCT03975205Lymphoma Leukemia · IndiaEarly 1UNKNOWNsutphin-drugsOct 31, 2019500
NCT03283696Sarcoma · United States, Germany, Italy1CompletedEli LillyApr 29, 201924
NCT03056599Sarcoma · United States1Completedpresage-biosciencesJul 22, 202123
NCT02783599Sarcoma · United States, France, Italy and more1CompletedEli LillyJul 5, 201851
NCT02677116Neoplasm Metastasis · United States, Japan1CompletedEli LillyOct 10, 201868
NCT02076620Sarcoma · Germany, Italy1CompletedPhilogenJan 25, 201829
NCT01815294Neoplasms · United States, Belgium, Spain and more1CompletedJohnson & JohnsonDec 201454
NCT01655693Carcinoma, Hepatocellular · United States, Austria, Belgium and more3CompletedValerio TherapeuticsMay 2017397
NCT01131364Breast Neoplasms · Italy2TerminatedPhilogenMar 201229
NCT00988195Neoplasms · Hong Kong1Completedbio-cancer-treatment-international-limitedAug 200915
NCT00461344Carcinoma, Ductal2TerminatedSanofiJun 200520
NCT00365365Breast Neoplasms · United States2CompletedSanofiOct 2011214
NCT00312208Breast Neoplasms · United States, Argentina, Australia and more3CompletedSanofiOct 20083,299
NCT00294996Breast Neoplasms · United States, Argentina, Canada and more3UNKNOWNsopherion-therapeutics363
NCT00250874Breast Neoplasms · Italy2UNKNOWNTeva Pharmaceutical Industries45
NCT00244127Aggressive Non-Hodgkin's Lymphoma in the Elderly. · France, Germany, Italy and more2UNKNOWNTeva Pharmaceutical Industries75
NCT00216645Ovarian Neoplasms2CompletedJohnson & Johnson74
NCT00191789Breast Neoplasms · India2CompletedEli LillyApr 200965
NCT00115414Breast Neoplasms2CompletedAmgen
NCT00103506Multiple Myeloma · United States, Argentina, Australia and more3CompletedJohnson & JohnsonMay 2014646
NCT00102609Sarcoma1CompletedJohnson & Johnson41
NCT00102219Breast Neoplasms · Brazil, Greece, Hungary and more2CompletedEli Lilly77
NCT00082472Neoplasm Metastasis · United States2UNKNOWNzivena30
NCT00057382Carcinoma, Hepatocellular · United States, Brazil, China and more3TerminatedAmgen750
NCT00021255Breast Neoplasms · United States, Argentina, Australia and more3CompletedSanofiDec 20143,222
NCT00005960Pain · United States2UNKNOWNAmgen
NCT00002319Sarcoma, Kaposi · United States3CompletedSequus Pharmaceuticals
NCT00002318Sarcoma, Kaposi · United States3UNKNOWNSequus Pharmaceuticals225
NCT00002147Sarcoma, Kaposi · United States3CompletedSequus Pharmaceuticals
NCT00002105Sarcoma, Kaposi · United States3CompletedSequus Pharmaceuticals220
NCT00003034Mesothelioma, Malignant · United States, Germany, Italy and more3UNKNOWNalfacellFeb 2008300

How it is read

Names in the registry

  • “Doxorubicin”, 29 entries
  • “doxorubicin hydrochloride”, 6 entries
  • “Doxorubicin hydrochloride (liposomal)”, 4 entries
  • “doxorubicin”, 3 entries
  • “CHOP”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.